Bloomage Biotech(SH:688363) Sou Hu Cai Jing·2025-05-15 06:13Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Composite Index (000680) decreased by 1.41% as of May 15, 2025, with mixed performance among constituent stocks [3] - Leading gainers included Junzhixing (688655) up 7.70%, Huaxi Biological (688363) up 6.56%, and Wanrun New Energy (688275) up 6.22%, while leading decliners were Changguang Huaxin (688048) down 8.10%, Huafeng Technology (688629) down 7.95%, and Aerospace Nanhu (688552) down 7.21% [3] - The Huaxia Sci-Tech Innovation Index ETF (589000) fell by 1.48%, with the latest price at 0.93 yuan, but showed a cumulative increase of 0.64% over the past two weeks as of May 14, 2025 [3] Group 2 - The Huaxia Sci-Tech Innovation Index ETF (589000) recorded a turnover rate of 3.73% during the trading session, with a transaction volume of 104 million yuan [3] - Over the past week, the average daily transaction volume of the Huaxia Sci-Tech Innovation Index ETF was 192 million yuan, ranking first among comparable funds [3] - In terms of scale and shares, the Huaxia Sci-Tech Innovation Index ETF saw an increase of 1.902 billion yuan in scale and 1.988 billion shares in volume over the past month, leading among comparable funds [3] Group 3 - The pharmaceutical sector is showing continuous signs of performance improvement for 2024 and Q1 2025, with overall profitability on the rise [4] - The sector is experiencing a gradual clearing of inventory and the impact of anti-corruption measures, with notable performance in sub-sectors such as chemical pharmaceuticals and medical consumables [4] - The overall R&D expense ratio for the pharmaceutical sector is expected to rebound year-on-year in 2024, laying a foundation for long-term stable development [4]